John Kirby, MD
Internal Medicine · Jefferson City, TNNPI 1275539835
Payments from drug & device makers
Across 288 payments — averaging $4057.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$408K
- GSK$187K
- Eli Lilly$170K
- Vivus LLC$131K
- AbbVie$93K
- Regeneron$88K
- plus $92K from 35 others
Across 26 payments — averaging $175.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
- Gilead$1K
- AbbVie$978
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $408,140 |
| GSK | 25 | $187,087 |
| Eli Lilly | 5 | $170,078 |
| Vivus LLC | 9 | $131,083 |
| AbbVie(2 entities) | 65 | $92,591 |
| Regeneron | 32 | $87,624 |
| Sanofi US Services Inc. | 15 | $44,038 |
| Pfizer | 27 | $16,832 |
| F. Hoffmann-la Roche AG | 2 | $12,608 |
| Gilead | 5 | $11,201 |
| Genentech, Inc. | 3 | $5,829 |
| Novo Nordisk | 22 | $374 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $136 |
| Dexcom, Inc. | 5 | $90 |
| Lilly USA, LLC | 5 | $80 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| Sequel Med Tech, LLC | 2 | $59 |
| Amgen | 4 | $54 |
| Bayer | 4 | $52 |
| Heartflow, Inc. | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Medtronic | 2 | $42 |
| Harmony Biosciences LLC | 2 | $41 |
| Boston Scientific | 1 | $39 |
| Amarin Pharma, Inc. | 2 | $29 |
| Johnson & Johnson | 2 | $25 |
| AstraZeneca | 2 | $24 |
| Abbott | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Seqirus USA Inc | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
| Welch Allyn | 1 | $13 |
| Merck | 1 | $12 |
| Si-bone, Inc. | 1 | $12 |
| Insulet Corporation | 1 | $11 |
How this compares
$1,168,558 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Jefferson City
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- Charles CrumpChattanooga$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.